SCHEMBL413011

SCHEMBL413011

Nc1c(Cl)ccnc1Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29486472 1.00
SCHEMBL29479544 0.81
SCHEMBL337291 0.81
SCHEMBL1056076 0.81
SCHEMBL29738526 0.81
Hydrochloric Acid SCHEMBL27415656 0.79 NR4A2 (0.41)
SCHEMBL25404805 0.77
SCHEMBL12263788 0.77
SCHEMBL12395177 0.77
SCHEMBL1223407 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104447244-A Roflumilast intermediates and preparation method of roflumilast CHENGDU SENKE PHARMACEUTICAL CO LTD 2015-03-25 CN claimed
CN-104447245-A Roflumilast intermediates, preparation methods of intermediates and preparation method of roflumilast CHENGDU SENKE PHARMACEUTICAL CO LTD 2015-03-25 CN claimed
US-12565496-B2 Substituted 1H-pyrrolo[3,2-b]pyridine compounds and methods of use thereof BAYER AKTIENGESELLSCHAFT (DE) 2026-03-03 US disclosed
US-12472181-B2 Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders GALAPAGOS NV (BE) 2025-11-18 US disclosed
US-20250179059-A1 ANTICANCER COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2025-06-05 US disclosed
WO-2025043225-A2 DEGRADERS OF CYCLIN-DEPENDENT KINASE 2 GENENTECH, INC. (US) 2025-02-27 WO disclosed
EP-4509122-A2 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF Bayer Aktiengesellschaft (DE) 2025-02-19 EP disclosed
US-12162870-B2 Anticancer compounds THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-12-10 US disclosed
EP-4188930-B1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF BAYER AG (DE) 2024-10-23 EP disclosed
US-20240325404-A1 TREATMENT OF INFLAMMATORY DISEASES GALAPAGOS NV (BE) 2024-10-03 US disclosed
US-12083121-B2 Substituted piperazines as KRAS G12C inhibitors AMGEN INC. (US) 2024-09-10 US disclosed
EP-0758897-A4 COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES RHONE POULENC RORER PHARMA (US) 1997-11-19 EP disclosed
US-5652366-A ADENOSINE AGONISTS; HYPOTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC, AND ANTILIPOLYTIC AGENTS RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1997-07-29 US disclosed
WO-1997024327-A1 PROCESS FOR PREPARING 2,4-DIHYDROXYPYRIDINE AND 2,4-DIHYDROXY-3-NITROPYRIDINE RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1997-07-10 WO disclosed
CN-1148811-A Compound having antihypertensive, cardioprotective, anti-ischemic and antilipolytic functions RHONE POULENC RORER PHARMA (US) 1997-04-30 CN disclosed
EP-0758897-A1 COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) 1997-02-26 EP disclosed
US-5561134-A ADENOSINE DERIVATIVES RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1996-10-01 US disclosed
WO-1995028160-A1 COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1995-10-26 WO disclosed
US-5364862-A Adenosine derivatives RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1994-11-15 US disclosed
EP-0277599-A2 Fluorine containing cyclopentane derivatives and processes for their production ASAHI GLASS COMPANY LTD. (JP) 1988-08-10 EP disclosed